How effective is Flexeril for Insomnia? (a real world drug study)

Summary:

Overall ratings: 3.5/5
Long term ratings: 3.8/5

This is a phase IV clinical study of how effective Flexeril (cyclobenzaprine hydrochloride) is for Insomnia and for what kind of people. The study is created by eHealthMe from 15 Flexeril users and is updated continuously.

What is Flexeril?

Flexeril has active ingredients of cyclobenzaprine hydrochloride. It is often used in muscle spasms. eHealthMe is studying from 38,306 Flexeril users. Check the latest studies of Flexeril.

What is Insomnia?

Insomnia (sleeplessness) is found to be associated with 3,118 drugs and 5,156 conditions by eHealthMe. Check the latest studies of Insomnia.


On Mar, 09, 2026

15 people are studied for taking Flexeril in Insomnia

Overall effectiveness (number of people):

Does Flexeril work for your Insomnia (overall)?

Long term (1+ years) effectiveness (number of people):

Does Flexeril work for your Insomnia (long term)?

Flexeril effectiveness for Insomnia (number of people):

Overall:
  • not at all: 1
  • somewhat: 1
  • moderate: 5
  • high: 6
  • very high: 2
Long Term:
  • not at all: 0
  • somewhat: 1
  • moderate: 2
  • high: 4
  • very high: 2

Gender of people who take Flexeril for Insomnia *:

  • female: 66.67 %
  • male: 33.33 %

Age of people who take Flexeril for Insomnia *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 6.67 %
  • 20-29: 6.67 %
  • 30-39: 40.0 %
  • 40-49: 6.67 %
  • 50-59: 13.33 %
  • 60+: 26.67 %

Who find Flexeril more effective for Insomnia?

Gender of people who take Flexeril for Insomnia *:

  • female: 50 %
  • male: 50 %

Age of people who take Flexeril for Insomnia *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 12.5 %
  • 30-39: 37.5 %
  • 40-49: 0.0 %
  • 50-59: 25.0 %
  • 60+: 25.0 %

* Approximation only. Some reports may have incomplete information.

Do you take Flexeril?

- You can start a phase IV clinical trial to monitor Flexeril safety and effectiveness.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Alternative drugs to, pros and cons of:

Treatments, associated drugs and conditions:

How the study uses the data?

The study is based on cyclobenzaprine hydrochloride (the active ingredients of Flexeril) and Flexeril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: